Zeng Hui, Fang Cheng, Nam Seungyoon, Cai Qing, Long Xinghua
Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Cancer Genomics Branch, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, Republic of Korea.
Biomed Res Int. 2014;2014:724209. doi: 10.1155/2014/724209. Epub 2014 Aug 3.
Previous studies demonstrated that the associations between expression level of microRNA-155 (miR-155) and clinicopathological significance of breast cancer remained inconsistent. Therefore, we performed a meta-analysis based on eligible studies to summarize the possible associations.
We identified eligible studies published up to May 2014 by a comprehensive search of PubMed, EMBASE, CNKI, and VIP databases. The analysis was performed with RevMan. 5.0 software.
A total of 15 studies were included. The results of meta-analysis showed that miR-155 was positively correlated with breast cancer with standardized mean difference (SMD) = 1.22. Elevated miR-155 was found in Her-2 positive or lymph node metastasis positive, or p53 mutant type breast cancer. But the result showed to be insignificant in TNM comparison. With respect to estrogen receptor alpha (ER) and progesterone receptor (PR) status, both of them showed significant associations with SMD = -1.2 and -1.85, respectively.
MiR-155 detection might have a diagnostic value in breast cancer patients. It might be used as an auxiliary biomarker for different clinicopathological breast cancer.
既往研究表明,微小RNA-155(miR-155)表达水平与乳腺癌临床病理意义之间的关联仍不一致。因此,我们基于符合条件的研究进行了一项荟萃分析,以总结可能的关联。
我们通过全面检索PubMed、EMBASE、中国知网(CNKI)和维普数据库(VIP),确定截至2014年5月发表的符合条件的研究。使用RevMan 5.0软件进行分析。
共纳入15项研究。荟萃分析结果显示,miR-155与乳腺癌呈正相关,标准化均数差(SMD)=1.22。在人表皮生长因子受体2(Her-2)阳性或淋巴结转移阳性或p53突变型乳腺癌中发现miR-155升高。但在TNM分期比较中结果显示无统计学意义。关于雌激素受体α(ER)和孕激素受体(PR)状态,两者均显示出显著关联,SMD分别为-1.2和-1.85。
miR-155检测可能对乳腺癌患者具有诊断价值。它可能用作不同临床病理类型乳腺癌的辅助生物标志物。